Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

PMID:
30190369
2.

Visualisation of the insertion of a membrane for the treatment of preterm rupture of fetal membranes using a synthetic model of a pregnant uterus.

Roman S, Hillary C, Narice B, Bullock AJ, Anumba DO, MacNeil S.

J Biomater Appl. 2018 Aug;33(2):234-244. doi: 10.1177/0885328218786038. Epub 2018 Jul 12.

PMID:
29996717
3.

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.

Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.

Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.

PMID:
29961768
4.

Pain and modifiable risk factors among weight loss seeking Veterans with overweight.

Godfrey KM, Bullock AJ, Dorflinger LM, Min KM, Ruser CB, Masheb RM.

Appetite. 2018 Sep 1;128:100-105. doi: 10.1016/j.appet.2018.06.010. Epub 2018 Jun 6.

PMID:
29885382
5.

Does food addiction contribute to excess weight among clinic patients seeking weight reduction? Examination of the Modified Yale Food Addiction Survey.

Masheb RM, Ruser CB, Min KM, Bullock AJ, Dorflinger LM.

Compr Psychiatry. 2018 Jul;84:1-6. doi: 10.1016/j.comppsych.2018.03.006. Epub 2018 Apr 4.

PMID:
29654930
6.

Developing improved tissue-engineered buccal mucosa grafts for urethral reconstruction.

Simsek A, Bullock AJ, Roman S, Chapple CR, Macneil S.

Can Urol Assoc J. 2018 May;12(5):E234-E242. doi: 10.5489/cuaj.4826. Epub 2018 Feb 6.

7.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE.

J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

PMID:
29232172
8.

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM.

JAMA Oncol. 2018 Mar 8;4(3):e173420. doi: 10.1001/jamaoncol.2017.3420. Epub 2018 Mar 8.

9.

Gastrointestinal Tract Malignancies: Obstacles and Advancements.

Bullock AJ.

Clin Ther. 2017 Nov;39(11):2122-2124. doi: 10.1016/j.clinthera.2017.10.001. Epub 2017 Oct 17. No abstract available.

PMID:
29050640
10.

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.

Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM.

Br J Cancer. 2017 Dec 5;117(12):1874-1882. doi: 10.1038/bjc.2017.349. Epub 2017 Oct 5.

11.

Surgical Management of Gallbladder Cancer: Simple Versus Extended Cholecystectomy and the Role of Adjuvant Therapy.

Kasumova GG, Tabatabaie O, Najarian RM, Callery MP, Ng SC, Bullock AJ, Fisher RA, Tseng JF.

Ann Surg. 2017 Oct;266(4):625-631. doi: 10.1097/SLA.0000000000002385.

PMID:
28692469
12.

Cancer Genomics: Targeting Inherited Risk and Somatic Mutations in Precision Oncology.

Bullock AJ.

Clin Ther. 2016 Jul;38(7):1548-50. doi: 10.1016/j.clinthera.2016.03.037. Epub 2016 Apr 22. No abstract available.

PMID:
27101819
13.

Developing Repair Materials for Stress Urinary Incontinence to Withstand Dynamic Distension.

Hillary CJ, Roman S, Bullock AJ, Green NH, Chapple CR, MacNeil S.

PLoS One. 2016 Mar 16;11(3):e0149971. doi: 10.1371/journal.pone.0149971. eCollection 2016.

14.

Development of an implantable synthetic membrane for the treatment of preterm premature rupture of fetal membranes.

Roman S, Bullock AJ, Anumba DO, MacNeil S.

J Biomater Appl. 2016 Feb;30(7):995-1003. doi: 10.1177/0885328215612500. Epub 2015 Oct 20.

PMID:
26491057
15.

Production of ascorbic acid releasing biomaterials for pelvic floor repair.

Mangır N, Bullock AJ, Roman S, Osman N, Chapple C, MacNeil S.

Acta Biomater. 2016 Jan;29:188-197. doi: 10.1016/j.actbio.2015.10.019. Epub 2015 Oct 19.

16.

Biomaterials for pelvic floor reconstructive surgery: how can we do better?

Gigliobianco G, Regueros SR, Osman NI, Bissoli J, Bullock AJ, Chapple CR, MacNeil S.

Biomed Res Int. 2015;2015:968087. doi: 10.1155/2015/968087. Epub 2015 Apr 21. Review.

17.

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS.

Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14.

18.

Tissue engineered buccal mucosa for urethroplasty: progress and future directions.

Osman NI, Hillary C, Bullock AJ, MacNeil S, Chapple CR.

Adv Drug Deliv Rev. 2015 Mar;82-83:69-76. doi: 10.1016/j.addr.2014.10.006. Epub 2014 Oct 16. Review.

PMID:
25451857
19.

The effect of ascorbic acid and fluid flow stimulation on the mechanical properties of a tissue engineered pelvic floor repair material.

Osman NI, Roman S, Bullock AJ, Chapple CR, MacNeil S.

Proc Inst Mech Eng H. 2014 Sep;228(9):867-75. doi: 10.1177/0954411914549393.

PMID:
25313023
20.

Acute in vivo response to an alternative implant for urogynecology.

Roman Regueros S, Albersen M, Manodoro S, Zia S, Osman NI, Bullock AJ, Chapple CR, Deprest J, MacNeil S.

Biomed Res Int. 2014;2014:853610. doi: 10.1155/2014/853610. Epub 2014 Jul 17.

21.

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.

Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS.

Transl Oncol. 2014 Apr;7(2):188-95. doi: 10.1016/j.tranon.2014.02.003. Epub 2014 Mar 4.

22.

Tissue engineering airway mucosa: a systematic review.

Hamilton N, Bullock AJ, Macneil S, Janes SM, Birchall M.

Laryngoscope. 2014 Apr;124(4):961-8. doi: 10.1002/lary.24469. Epub 2013 Nov 19. Review.

PMID:
24129819
23.

Developing a tissue engineered repair material for treatment of stress urinary incontinence and pelvic organ prolapse-which cell source?

Roman S, Mangera A, Osman NI, Bullock AJ, Chapple CR, MacNeil S.

Neurourol Urodyn. 2014 Jun;33(5):531-7. doi: 10.1002/nau.22443. Epub 2013 Jul 19.

PMID:
23868812
24.

Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair.

Mangera A, Bullock AJ, Roman S, Chapple CR, MacNeil S.

BJU Int. 2013 Sep;112(5):674-85. doi: 10.1111/bju.12186. Epub 2013 Jun 14.

25.

Skin stem cell hypotheses and long term clone survival--explored using agent-based modelling.

Li X, Upadhyay AK, Bullock AJ, Dicolandrea T, Xu J, Binder RL, Robinson MK, Finlay DR, Mills KJ, Bascom CC, Kelling CK, Isfort RJ, Haycock JW, MacNeil S, Smallwood RH.

Sci Rep. 2013;3:1904. doi: 10.1038/srep01904.

26.

High molecular weight plant heteropolysaccharides stimulate fibroblasts but inhibit keratinocytes.

Shahbuddin M, Shahbuddin D, Bullock AJ, Ibrahim H, Rimmer S, MacNeil S.

Carbohydr Res. 2013 Jun 28;375:90-9. doi: 10.1016/j.carres.2013.04.006. Epub 2013 Apr 13.

PMID:
23694709
27.

Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse: comment on Boennelycke et al.

Osman NI, Roman S, Gigliobianco G, Mangera A, Bullock AJ, Chapple CR, MacNeil S.

Int Urogynecol J. 2013 May;24(5):881. doi: 10.1007/s00192-012-2023-5. No abstract available.

PMID:
23287966
28.

Understanding patients' attitudes toward communication about the cost of cancer care.

Bullock AJ, Hofstatter EW, Yushak ML, Buss MK.

J Oncol Pract. 2012 Jul;8(4):e50-8. doi: 10.1200/JOP.2011.000418. Epub 2012 Feb 28.

29.

Postproduction processing of electrospun fibres for tissue engineering.

Bye FJ, Wang L, Bullock AJ, Blackwood KA, Ryan AJ, MacNeil S.

J Vis Exp. 2012 Aug 9;(66). pii: 4172. doi: 10.3791/4172.

30.

Mesh social networking: a patient-driven process.

Osman NI, Mangera A, Roman S, Bullock AJ, MacNeil S, Chapple CR.

BJU Int. 2012 Jun;109(12):E45-6; author reply E46. doi: 10.1111/j.1464-410X.2012.11235_3.x. No abstract available.

31.

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review.

Mangera A, Bullock AJ, Chapple CR, Macneil S.

Neurourol Urodyn. 2012 Jan;31(1):13-21. doi: 10.1002/nau.21156. Epub 2011 Oct 28. Review.

PMID:
22038890
32.

Methods to reduce the contraction of tissue-engineered buccal mucosa for use in substitution urethroplasty.

Patterson JM, Bullock AJ, MacNeil S, Chapple CR.

Eur Urol. 2011 Oct;60(4):856-61. doi: 10.1016/j.eururo.2011.07.045. Epub 2011 Jul 26.

PMID:
21803482
33.

Developing biodegradable scaffolds for tissue engineering of the urethra.

Selim M, Bullock AJ, Blackwood KA, Chapple CR, MacNeil S.

BJU Int. 2011 Jan;107(2):296-302. doi: 10.1111/j.1464-410X.2010.09310.x.

34.

Development of a calcium-chelating hydrogel for treatment of superficial burns and scalds.

Bullock AJ, Pickavance P, Haddow DB, Rimmer S, MacNeil S.

Regen Med. 2010 Jan;5(1):55-64. doi: 10.2217/rme.09.67.

PMID:
20017694
35.

Co-culture of intestinal epithelial and stromal cells in 3D collagen-based environments.

Viney ME, Bullock AJ, Day MJ, MacNeil S.

Regen Med. 2009 May;4(3):397-406. doi: 10.2217/rme.09.4.

36.

Inhibition of keratinocyte-driven contraction of tissue-engineered skin in vitro by calcium chelation and early restraint but not submerged culture.

Thornton DJ, Harrison CA, Heaton MJ, Bullock AJ, MacNeil S.

J Burn Care Res. 2008 Mar-Apr;29(2):369-77. doi: 10.1097/BCR.0b013e318166da8c.

PMID:
18354296
37.

Decellularization and sterilization of porcine urinary bladder matrix for tissue engineering in the lower urinary tract.

Rosario DJ, Reilly GC, Ali Salah E, Glover M, Bullock AJ, Macneil S.

Regen Med. 2008 Mar;3(2):145-56. doi: 10.2217/17460751.3.2.145.

38.

Randomized, controlled, single-blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers.

Moustafa M, Bullock AJ, Creagh FM, Heller S, Jeffcoate W, Game F, Amery C, Tesfaye S, Ince Z, Haddow DB, MacNeil S.

Regen Med. 2007 Nov;2(6):887-902.

39.

Use of an in vitro model of tissue-engineered skin to investigate the mechanism of skin graft contraction.

Harrison CA, Gossiel F, Layton CM, Bullock AJ, Johnson T, Blumsohn A, MacNeil S.

Tissue Eng. 2006 Nov;12(11):3119-33.

PMID:
17518627
40.

Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue-engineered skin.

Harrison CA, Layton CM, Hau Z, Bullock AJ, Johnson TS, MacNeil S.

Br J Dermatol. 2007 Feb;156(2):247-57.

PMID:
17223863
41.

The effect of induced biphasic pulsed currents on re-epithelialization of a novel wound healing model.

Bullock AJ, Barker AT, Coulton L, Macneil S.

Bioelectromagnetics. 2007 Jan;28(1):31-41.

PMID:
16988995
42.
43.

Investigation of keratinocyte regulation of collagen I synthesis by dermal fibroblasts in a simple in vitro model.

Harrison CA, Gossiel F, Bullock AJ, Sun T, Blumsohn A, Mac Neil S.

Br J Dermatol. 2006 Mar;154(3):401-10.

PMID:
16445767
44.

Tissue-engineered buccal mucosa for substitution urethroplasty.

Bhargava S, Chapple CR, Bullock AJ, Layton C, MacNeil S.

BJU Int. 2004 Apr;93(6):807-11.

45.

Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women.

Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ.

Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):687-93.

PMID:
12512245
46.
47.

Developmental changes in intracellular pH buffering power in smooth muscle.

Bullock AJ, Duquette RA, Buttell N, Wray S.

Pflugers Arch. 1998 Mar;435(4):575-7.

PMID:
9446707
48.
49.

The role of the sarcolemmal Ca(2+)-ATPase in the pH transients associated with contraction in rat smooth muscle.

Naderali EK, Buttell N, Taggart MJ, Bullock AJ, Eisner DA, Wray S.

J Physiol. 1997 Dec 1;505 ( Pt 2):329-36.

50.

Supplemental Content

Loading ...
Support Center